Merck's life science business division last week announced a US$65m expansion of its HPAPI and ADC manufacturing capabilities and capacity at its facility near Madison, Wisconsin.
Merck and Seattle Genetics have announced two strategic oncology collaborations: one to develop Seattle Genetics’ antibody-drug conjugate ladiratuzumab vedotin worldwide; and another to accelerate the global reach of Tukysa (tucatinib).
In a deal valued at US$21bn, Gilead Sciences is to acquire Immunomedics Inc, a New Jersey headquartered biotech that has been highly focused on breast cancer drug innovation.
Antibody-focused service providers merge their offerings to create a ‘seamless workflow’ on antibody-drug conjugates to help save developers’ time and costs.
Under an agreement with Zumutor, Catalent Biologics initiates clinical manufacture of the latter’s lead candidate targeting solid tumors, ahead of FDA filing.
Aiming to facilitate and accelerate discovery of biologics, Aridis’ Apex platform can also discover antibodies against viruses ‘within one day of a pandemic’.
Almirall enters drug discovery agreement with WuXi Biologics, gaining access to the WuXiBody platform to develop antibodies for the treatment of dermatological diseases.
US FDA approves AstraZeneca’s at-home autoinjector for administration of an add-on treatment for severe asthma, matching the indication of GSK’s rival product, Nucala.
Lonza already manufacturers three out of five commercially available ADCs but is preparing for additional demand with a two-year expansion project at its Visp site.
